You are here

  • Home
  • Archive
  • Volume 82, Issue 4
  • Correspondence on ‘Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden’

Article Text

Article menu

This article has a Reply. Please see:

Download PDFPDF
Correspondence
Correspondence on ‘Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden’
  1. Maria I Zervou1,
  2. George N Goulielmos1,2
  1. 1 Section of Molecular Pathology and Human Genetics, Department of Internal Medicine, School of Medicine, University of Crete, Heraklion, Greece
  2. 2 Department of Internal Medicine, University Hospital of Heraklion, Heraklion, Greece
  1. Correspondence to Dr George N Goulielmos, Department of Medicine, University of Crete, Rethimno, Crete, Greece; goulielmos{at}med.uoc.gr

http://dx.doi.org/10.1136/annrheumdis-2021-219894

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with great interest an article by Molander et al 1 demonstrating a strong association between clinical rheumatoid arthritis (RA) disease activity, measured by Disease Avtivity Score-28 (DAS28) ESR, and the risk of venous thromboembolism (VTE). In the framework of this elegant nationwide register-based cohort study that enrolled 46 316 patients, it was found that the risk ratio for VTE in patients with RA was 1.88 (95% CI 1.65 to 2.15), while among patients with RA, the risk for VTE increased with increasing RA disease activity. Noteworthy, compared with the general population, also patients with RA in DAS28 ESR remission were at elevated VTE risk.1 Therefore, the authors nicely suggested that RA disease activity can be used as an additional tool for VTE risk stratification in patients with RA. RA is …

    View Full Text

    Footnotes

    • Contributors MIZ wrote the paper. GNG reviewed and edited the manuscript. Both authors read and approved its final form.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles